42 related articles for article (PubMed ID: 19476988)
1. A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors.
Chuk MK; Aikin A; Whitcomb T; Widemann BC; Zannikos P; Bayever E; Balis FM; Fox E
Pediatr Blood Cancer; 2012 Nov; 59(5):865-9. PubMed ID: 22847981
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.
Powell MA; Sill MW; Goodfellow PJ; Benbrook DM; Lankes HA; Leslie KK; Jeske Y; Mannel RS; Spillman MA; Lee PS; Hoffman JS; McMeekin DS; Pollock PM
Gynecol Oncol; 2014 Oct; 135(1):38-43. PubMed ID: 25019571
[TBL] [Abstract][Full Text] [Related]
3. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
Coleman RL; Sill MW; Lankes HA; Fader AN; Finkler NJ; Hoffman JS; Rose PG; Sutton GP; Drescher CW; McMeekin DS; Hu W; Deavers M; Godwin AK; Alpaugh RK; Sood AK
Gynecol Oncol; 2012 Dec; 127(3):538-43. PubMed ID: 22922531
[TBL] [Abstract][Full Text] [Related]
4. Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO).
Lindemann K; Malander S; Christensen RD; Mirza MR; Kristensen GB; Aavall-Lundqvist E; Vergote I; Rosenberg P; Boman K; Nordstrøm B
BMC Cancer; 2014 Feb; 14():68. PubMed ID: 24498853
[TBL] [Abstract][Full Text] [Related]
5. Drug Monographs: Trabectedin and Trifluridine-Tipiracil.
Solimando DA; Waddell JA
Hosp Pharm; 2016 Feb; 51(2):120-128. PubMed ID: 38746764
[TBL] [Abstract][Full Text] [Related]
6. Recurrent Endometrial Cancer: Local and Systemic Treatment Options.
Rütten H; Verhoef C; van Weelden WJ; Smits A; Dhanis J; Ottevanger N; Pijnenborg JMA
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944893
[TBL] [Abstract][Full Text] [Related]
7. Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers.
El Bairi K; Amrani M; Afqir S
Cancer Med; 2018 Jun; 7(6):2221-2246. PubMed ID: 29732738
[TBL] [Abstract][Full Text] [Related]
8. Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study.
Angarita FA; Cannell AJ; Abdul Razak AR; Dickson BC; Blackstein ME
BMC Cancer; 2016 Jan; 16():30. PubMed ID: 26786213
[TBL] [Abstract][Full Text] [Related]
9. Prolonged response to trabectedin in a heavily pretreated patient with metastatic endometrial carcinoma: A case report and literature review.
Meoni G; Cecere FL; Chaib I; Giommoni E; Di Costanzo F
Gynecol Oncol Case Rep; 2011; 2(1):23-5. PubMed ID: 24371606
[TBL] [Abstract][Full Text] [Related]
10. Drug induced rhabdomyolysis.
Hohenegger M
Curr Opin Pharmacol; 2012 Jun; 12(3):335-9. PubMed ID: 22560920
[TBL] [Abstract][Full Text] [Related]
11. A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials.
Le Cesne A; Yovine A; Blay JY; Delaloge S; Maki RG; Misset JL; Frontelo P; Nieto A; Jiao JJ; Demetri GD
Invest New Drugs; 2012 Jun; 30(3):1193-202. PubMed ID: 21484250
[TBL] [Abstract][Full Text] [Related]
12. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.
Massuti B; Cobo M; Camps C; Dómine M; Provencio M; Alberola V; Viñolas N; Rosell R; Tarón M; Gutiérrez-Calderón V; Lardelli P; Alfaro V; Nieto A; Isla D
Lung Cancer; 2012 Jun; 76(3):354-61. PubMed ID: 22197612
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
[TBL] [Abstract][Full Text] [Related]
14. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma.
Simpson EL; Rafia R; Stevenson MD; Papaioannou D
Health Technol Assess; 2010 May; 14 Suppl 1():63-7. PubMed ID: 20507805
[TBL] [Abstract][Full Text] [Related]
15. Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.
Le Cesne A; Reichardt P
Future Oncol; 2015; 11(11 Suppl):3-14. PubMed ID: 26043310
[TBL] [Abstract][Full Text] [Related]
16. Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study.
McMeekin DS; Lisyanskaya A; Crispens M; Oza AM; Braly P; Doering D; Bayever E; Michiels B; Markman M
Gynecol Oncol; 2009 Aug; 114(2):288-92. PubMed ID: 19476988
[TBL] [Abstract][Full Text] [Related]
17. Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer.
Adam JP; Boumedien F; Letarte N; Provencher D
Gynecol Oncol; 2017 Oct; 147(1):47-53. PubMed ID: 28751117
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
